Figure 1

Study design and clinical features following the IVIg administration with preventive and curative intent. Outlines of the experimental design for (a) preventive and (c) curative protocols. Mice were randomized to: PBS + 2% Maltose (n = 50), PBS + IVIg (n = 50), HOCl + Maltose (n = 50), HOCl + IVIg (n = 50) groups. Each group included 30 mice for the preventive protocol and 20 mice for the curative protocol. 300 µL of HOCl or PBS were administered by daily intradermal injection into the shaved backs of mice until sacrifice. 2 g/Kg of IVIg were administered in a single retro-orbital injection at d0 with preventive intent, and at d21 with curative intent. (b,d) Curves depicting skin thickness variation compared to D0, measured every 4 days during the whole experimental protocols, for each group. Data are quoted as mean ± SEM; *p < 0.05 versus PBS + 2% Maltose; **p < 0.01 versus PBS + 2% Maltose; ***p < 0.001 versus PBS + 2% Maltose; ****p < 0.0001 versus PBS + 2% Maltose; ^##p < 0.01 vs HOCl + 2% Maltose; ^###p < 0.001 versus HOCl + 2% Maltose. Data were analyzed by a Two-way ANOVA test with Tukey’s multiple comparisons.